Excellerate Bioscience
Excellerate Bioscience is a UK-based contract research organization (CRO) specializing in molecular and cellular pharmacology. They focus on providing high-quality, innovative services to support drug discovery programs across various therapeutic areas. Their mission is to deliver results efficiently, empowering clients to reach milestones through collaboration, expertise, transparency, and a results-driven approach.
Industries
Nr. of Employees
small (1-50)
Excellerate Bioscience
Nottingham, England, United Kingdom
Products
Bespoke CRO Lab Support
Custom assay development and laboratory support services backed by state-of-the-art facilities and experienced pharmacology and cell biology scientists.
Tailored Project Proposal
Customized project proposals outlining key research questions, recommended pharmacology and custom assay development solutions, timelines, and resource allocations.
Data Generation And Reporting
Rigorous experimental data generation, QC checks, and flexible data reporting tailored to preferred analysis software and databases.
Initial Consultations
Initial consultations for worldwide SME and pharma clients on projects covering all stages of preclinical drug discovery from target identification and validation through to preclinical candidate studies.
Bespoke CRO Lab Support
Custom assay development and laboratory support services backed by state-of-the-art facilities and experienced pharmacology and cell biology scientists.
Tailored Project Proposal
Customized project proposals outlining key research questions, recommended pharmacology and custom assay development solutions, timelines, and resource allocations.
Data Generation And Reporting
Rigorous experimental data generation, QC checks, and flexible data reporting tailored to preferred analysis software and databases.
Initial Consultations
Initial consultations for worldwide SME and pharma clients on projects covering all stages of preclinical drug discovery from target identification and validation through to preclinical candidate studies.
Services
Consultation to define research questions, assess risks and scope tailored project proposals for preclinical drug discovery programs.
Preparation of bespoke project proposals with recommended approaches, timelines, resource allocations and flexible commercial options (fee-for-service or monthly FTE).
Custom assay development and laboratory execution to meet client-specific experimental requirements, supported by state-of-the-art facilities and specialist collaborations where required.
End-to-end data workflows including QC checks, statistical scrutiny, tailored analysis and concise reporting to support project decision-making and milestone delivery.
Consultation to define research questions, assess risks and scope tailored project proposals for preclinical drug discovery programs.
Preparation of bespoke project proposals with recommended approaches, timelines, resource allocations and flexible commercial options (fee-for-service or monthly FTE).
Custom assay development and laboratory execution to meet client-specific experimental requirements, supported by state-of-the-art facilities and specialist collaborations where required.
End-to-end data workflows including QC checks, statistical scrutiny, tailored analysis and concise reporting to support project decision-making and milestone delivery.
Expertise Areas
- Preclinical drug discovery
- Molecular and cellular pharmacology
- Assay development and high-throughput screening
- Phenotypic screening and primary human cell biology
Key Technologies
- qPCR
- Flow cytometry
- Western blotting
- Immunofluorescence imaging
News & Updates
Excellerate Bioscience announces a new site location at Nottingham’s NG2 Business Park.
Research on a new treatment mechanism for diabesity published in a scientific journal.
A scientific publication on chemokine receptor pharmacology and fluorescent allosteric modulators.
Announcement of new staff appointments to strengthen immunology and pharmacology teams.
Partnership to provide ligand kinetic binding services.
Participation in an EU consortium to develop new obesity treatments.
Excellerate Bioscience announces a new site location at Nottingham’s NG2 Business Park.
Research on a new treatment mechanism for diabesity published in a scientific journal.
A scientific publication on chemokine receptor pharmacology and fluorescent allosteric modulators.
Announcement of new staff appointments to strengthen immunology and pharmacology teams.
Partnership to provide ligand kinetic binding services.
Participation in an EU consortium to develop new obesity treatments.